• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肥胖症纤溶酶系统的研究。

Studies on the fibrinolytic enzyme system in obesity.

作者信息

Bennett N B, Ogston C M, McAndrew G M, Ogston D

出版信息

J Clin Pathol. 1966 May;19(3):241-3. doi: 10.1136/jcp.19.3.241.

DOI:10.1136/jcp.19.3.241
PMID:4223015
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC473245/
Abstract

Plasma fibrinolytic activity, inhibitors of fibrinolysis, and fibrinogen were estimated in 34 subjects of varying ratio of observed to standard weight. The inverse relationship between fibrinolytic activity and the ratio of observed to standard weight was confirmed. No significant correlation was found between anti-plasmin or anti-urokinase and the ratio of observed to standard weight. It was therefore concluded that the decreased plasma fibrinolytic activity in obese subjects is due to decreased production of plasminogen activator rather than to excessive inhibition.

摘要

对34名实际体重与标准体重比例各异的受试者的血浆纤溶活性、纤溶抑制物和纤维蛋白原进行了评估。纤溶活性与实际体重和标准体重之比之间的负相关关系得到了证实。未发现抗纤溶酶或抗尿激酶与实际体重和标准体重之比之间存在显著相关性。因此得出结论,肥胖受试者血浆纤溶活性降低是由于纤溶酶原激活物生成减少而非抑制过度所致。

相似文献

1
Studies on the fibrinolytic enzyme system in obesity.肥胖症纤溶酶系统的研究。
J Clin Pathol. 1966 May;19(3):241-3. doi: 10.1136/jcp.19.3.241.
2
The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity.去纤苷的纤溶机制:去纤苷对纤溶酶活性的影响。
Blood Coagul Fibrinolysis. 2009 Dec;20(8):627-34. doi: 10.1097/MBC.0b013e32832da1e3.
3
The behavior of alpha2-plasmin inhibitor in fibrinolytic states.α2-纤溶酶抑制剂在纤溶状态下的行为。
J Clin Invest. 1977 Aug;60(2):361-9. doi: 10.1172/JCI108784.
4
Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.组织型纤溶酶原激活剂与尿激酶在体外的相对纤维蛋白溶解、纤溶及溶栓特性比较
Thromb Haemost. 1981 Jun 30;45(3):225-9.
5
[Proactivator-activator system in human plasma fibrinolysis: studies on the synthetic fibrinolytic system composed of functionally pure fibrinogen, plasminogen and proactivator, separated from human plasma].[人血浆纤维蛋白溶解中的前激活剂-激活剂系统:关于从人血浆中分离出的由功能纯的纤维蛋白原、纤溶酶原和前激活剂组成的合成纤维蛋白溶解系统的研究]
Nihon Seirigaku Zasshi. 1972 Mar;34(3):147-55.
6
Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.不同纤溶酶对含表面活性剂纤维蛋白的裂解作用。表面活性的溶解动力学及恢复情况。
Am J Respir Cell Mol Biol. 1999 Dec;21(6):738-45. doi: 10.1165/ajrcmb.21.6.3514.
7
Increased plasminogen activator (urokinase) in tissue culture after fibrin deposition.纤维蛋白沉积后组织培养中纤溶酶原激活物(尿激酶)增加。
J Clin Invest. 1973 Apr;52(4):823-34. doi: 10.1172/JCI107246.
8
The role of platelets in fibrinolysis. Studies on the plasminogen activator and anti-plasmin activity of platelets.
Br J Haematol. 1970 May;18(5):575-84. doi: 10.1111/j.1365-2141.1970.tb00779.x.
9
Highly potent fibrinolytic serine protease from Streptomyces.来自链霉菌的高效纤溶丝氨酸蛋白酶。
Enzyme Microb Technol. 2011 Jan 5;48(1):7-12. doi: 10.1016/j.enzmictec.2010.08.003. Epub 2010 Aug 18.
10
Fibrinolytic agents and their effects on the haemostatic system.纤维蛋白溶解剂及其对止血系统的影响。
Klin Wochenschr. 1988;66 Suppl 12:50-4.

引用本文的文献

1
Breast cancer stem cells, cytokine networks, and the tumor microenvironment.乳腺癌干细胞、细胞因子网络与肿瘤微环境。
J Clin Invest. 2011 Oct;121(10):3804-9. doi: 10.1172/JCI57099. Epub 2011 Oct 3.
2
Clinical experience with brinase.布瑞纳酶的临床经验。
J Clin Pathol. 1972 Jul;25(7):654-5. doi: 10.1136/jcp.25.7.654.
3
Platelet adhesiveness, coagulation, and fibrinolytic activity in obesity.肥胖症中的血小板黏附性、凝血及纤维蛋白溶解活性

本文引用的文献

1
A new method for the determination of fibrinogen in small samples of plasma.一种测定少量血浆样本中纤维蛋白原的新方法。
J Lab Clin Med. 1951 Feb;37(2):316-20.
2
FIBRINOLYSIS IN OBESITY.
Lancet. 1964 Dec 5;2(7371):1205-7. doi: 10.1016/s0140-6736(64)91042-6.
3
A new weight-for-height standard based on British anthropometric data.一项基于英国人体测量数据的新的身高别体重标准。
Br J Prev Soc Med. 1962 Oct;16(4):189-95. doi: 10.1136/jech.16.4.189.
J Clin Pathol. 1972 Jun;25(6):484-6. doi: 10.1136/jcp.25.6.484.
4
Acute changes in atherogenic and thrombogenic factors with cessation of smoking.戒烟后致动脉粥样硬化和血栓形成因素的急性变化。
J R Soc Med. 1990 Mar;83(3):146-8. doi: 10.1177/014107689008300306.
5
Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations.影响纤溶活性和血浆纤维蛋白原浓度的特征。
Br Med J. 1979 Jan 20;1(6157):153-6. doi: 10.1136/bmj.1.6157.153.
6
Epidemiology of venous thromboembolism.静脉血栓栓塞症的流行病学
Ann Surg. 1977 Aug;186(2):149-64. doi: 10.1097/00000658-197708000-00006.
4
Blood fibrinolytic activity in diabetes mellitus and its bearing on ischaemic heart disease and obesity.糖尿病患者的血液纤溶活性及其与缺血性心脏病和肥胖的关系。
Br Med J. 1963 Apr 6;1(5335):921-3. doi: 10.1136/bmj.1.5335.921.
5
The mechanism of clot dissolution by plasmin.纤溶酶溶解血栓的机制。
J Clin Invest. 1959 Jul;38(7):1086-95. doi: 10.1172/JCI103885.
6
Studies on enhanced fibrinolytic activity in man.关于人类纤维蛋白溶解活性增强的研究。
J Clin Invest. 1959 May;38(5):810-22. doi: 10.1172/JCI103863.